Mitochondrial DNA editing with mitoARCUS

. 2023 Dec;5(12):2039-2040.

doi: 10.1038/s42255-023-00933-5.

Affiliations

¹ Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
² Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. rh732@medschl.cam.ac.uk.

Denisa Hathazi et al. Nat Metab. 2023 Dec.

. 2023 Dec;5(12):2039-2040.

doi: 10.1038/s42255-023-00933-5.

¹ Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
² Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK. rh732@medschl.cam.ac.uk.

No abstract available

Cited by

Mitochondrial diseases: from molecular mechanisms to therapeutic advances.
Wen H, Deng H, Li B, Chen J, Zhu J, Zhang X, Yoshida S, Zhou Y. Wen H, et al. Signal Transduct Target Ther. 2025 Jan 10;10(1):9. doi: 10.1038/s41392-024-02044-3. Signal Transduct Target Ther. 2025. PMID: 39788934 Free PMC article. Review.

1. Hyslop, L. A. et al. Nature 534, 383–386 (2016). - DOI - PubMed - PMC
1. Silva-Pinheiro, P. et al. Nat. Commun. 13, 750 (2022). - DOI - PubMed - PMC
1. Zekonyte, U. et al. Nat. Commun. 12, 3210 (2021). - DOI - PubMed - PMC
1. Falabella, M., Minczuk, M., Hanna, M. G., Viscomi, C. & Pitceathly, R. D. S. Nat. Rev. Neurol. 18, 689–698 (2022). - DOI - PubMed
1. Barrera-Paez, J. D. & Moraes, C. T. Trends Genet. 38, 869–880 (2022). - DOI - PubMed - PMC